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Abstract
Background: Conflicting results have been reported regarding the association of gene
polymorphisms in the renin-angiotensin system (RAS) with different aspects of coronary artery
disease (CAD), such as myocardial infarction, neointimal hyperplasia or coronary artery
vasomotion. Since previous studies have linked angiotensin II to aneurysmal disease, our study
hypothesis was that RAS gene polymorphisms may be associated with aneurysm remodeling in
response to CAD.
Methods: The study population was selected from a series of 3862 consecutive patients who
underwent coronary angiography in our institution. One hundred and thirteen consecutive patients
with at least one coronary aneurysm (CA) were compared to 226 randomized control patients
without CA. DNA was extracted from white blood cells. The angiotensin-converting enzyme
(ACE) I/D and angiotensin type 1 receptor (AT1-R) A/C polymorphisms were detected using
previously published techniques.
Results: The distributions of the three ACE genotypes were similar in both groups: CA: 13%, 46%,
and 41% for II, ID, and DD respectively; controls: 18%, 41%, and 41% for II, ID, and DD respectively,
p = 0.45. The distributions of the three AT1-R genotypes were also similar in both groups: CA:
54%, 41%, and 5% for AA, AC, and CC respectively; controls: 55%, 33%, and 12%, for AA, AC, and
CC respectively, p = 0.08.
Conclusion: Our results provide further information on the role of RAS polymorphisms on
specific mechanisms implicated in CAD. Although an activated RAS may theoretically promote
aneurysm formation, the 2 RAS polymorphisms analyzed in this study are not associated with this
process in coronary arteries.
Background
Activation of the renin angiotensin system (RAS) plays an
important role in the pathogenesis of coronary artery dis-
ease (CAD).
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(ACE) are partly under genetic control [1]; circulating lev-
els of ACE are correlated with an insertion (I) / deletion
(D) polymorphism [2]: DD genotypes have higher levels
of ACE than either ID or II genotypes [3]. Although the
concept that genetic factors may increase the risk of CAD
via activation of the RAS is an attractive one, discordant
results have been published regarding the association of
the ACE I/D polymorphism with myocardial infarction.
While the initial study by Cambien et al reported an
increased frequency of the DD genotype in patients with
myocardial infarction [4], a large prospective study by
Lindpaintner et al did not confirm this association [5].
The effects of angiotensin II are exerted through the acti-
vation of specific high activity receptors [6]. A polymor-
phism located in the 3' untranslated region of the type 1
receptor (AT1-R) gene (corresponding to an adenine/gua-
nine substitution at the 1166 nucleotid position of the
mRNA) has been described [7]. Although it has been less
studied than the ACE I/D polymorphism, discordant
results have also been reported regarding the association
of the AT1-R polymorphism with myocardial infarction.
While Tiret et al reported synergistic effects of ACE and
AT1-R gene polymorphisms on the risk of myocardial inf-
arction [8], this was not confirmed in a recent study by
Steeds et al [9].
A possible explanation for these discrepancies is that myo-
cardial infarction is the results of a multifactorial process
implicating different mechanisms such as plaque progres-
sion, vessel remodeling, plaque rupture, thrombosis or
vasomotion [10,11]; each of these mechanisms may be
affected in one way or another by a given genotype but a
clear demonstration of the effect may be difficult if the
sole endpoint studied is the occurrence of myocardial inf-
arction. Smaller studies with carefully chosen intermedi-
ate end-points may be useful to elucidate the potential
impact of RAS polymorphisms on CAD. Previously, we
reported the relationships between RAS polymorphisms
and several specific mechanisms implicated in the patho-
genesis of CAD: the in vivo response to methylergonovine
was used to study coronary artery vasomotion [12]; reste-
nosis after stent implantation or balloon angioplasty were
used as models of neointimal hyperplasia or constrictive
remodeling [13,14]. In the present study, we sought to
investigate another form of abnormal vessel remodeling
in response to CAD: aneurysm formation.
Previous studies have linked angiotensin II to aneurysm
formation. In apo E -/- mice, angiotensin II infusion dra-
matically increased the extent of atherosclerosis and was
associated with the formation of large abdominal aortic
aneurysms [15]. Different mechanisms may be involved:
angiotensin II may promote development of aneurysms
by contributing to the inflammatory response [15,16],
altering smooth muscle cell migration [17], or inducing
matrix metalloproteinases production [18,19]. Aneurys-
mal coronary artery disease is characterized by abnormal
dilation of a localized or diffuse segment of the coronary
arterial tree. Approximately 1 to 5% of the patients with
coronary atherosclerosis have coronary aneurysm(s) (CA)
[20–23]. In the present study, we investigated whether the
ACE and AT1-R gene polymorphisms may be associated
with CA. Alleles and genotypes frequencies were com-




The study population was selected from a series of 3862
consecutive patients who underwent coronary angiogra-
phy in our institution. CA were defined as localized or dif-
fuse coronary dilations that exceeded the diameter of
normal adjacent segments by 1.5 times [21]. One hun-
dred and thirteen consecutive patients with evidence of
coronary atherosclerosis and at least one coronary aneu-
rysm were selected and constitute the CA group. During
the same period, we randomly selected 226 patients (2 :1
ratio) who presented with coronary atherosclerosis but
without CA to form the control group. Patients gave
informed consent for the study. We previously reported in
the same population the association between functional
polymorphisms in matrix metalloproteinase genes and
coronary aneurysms [24].
Clinical and Angiographic Data
Epidemiological and clinical characteristics were collected
by trained physicians. Coronary angiograms were ana-
lysed by two experienced interventionnal cardiologists.
The number of non significant (≤ 50%) or significant
(>50%) stenoses was recorded for each patient. The extent
of aneurysmal disease (number of segments and vessels
diseased per patient) was also noted as was the type (dif-
fuse or focal) of CA. Aneurysmal segment was classified as
focal when it involved a discrete portion of a segment with
adjacent normal segment within the same segment and
diffuse when the entire segment was dilated with no nor-
mal vessel within the segment [25]. Representative exam-
ples of diffuse and focal CA are shown in Figure 1.
The largest diameter of each aneurysmal vessel was meas-
ured by quantitative coronary angiography with use of the
CMS system as previously described [26].
Genetic Study
Genomic DNA was extracted from white blood cells by a
« salting out » procedure as previously described [27]. The
ACE fragment [13] containing the I/D sequence and AT1
receptor fragment containing the A/C -1166 substitutionPage 2 of 7
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Representative examples of coronary aneurysms: A. Diffuse aneurysmal disease of the right coronary artery. B. A focal coro-
nary aneurysm of the mid-portion of the right coronary artery (arrow)
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The ACE and AT1 receptor A/C polymorphisms were
detected as previously described [12].
Statistical Analysis
Statistical analysis was conducted with SAS software, ver-
sion 6.12 (SAS Institute Inc., Cary, NC). Mean values ± SD
were calculated for quantitative data. The quantitative var-
iables were compared between groups with use of
unpaired Student t tests. Qualitative variables were com-
pared by the Pearson's χ2-test, or the Fisher's exact test
when necessary.
Results
The baseline characteristics are presented in Tables 1 and
2. Except for male gender (CA group: 90%, control group:
80%; p = 0.02), previous myocardial infarction (CA
group: 68%, control group: 52%; p = 0.005) and an his-
tory of aortic aneurysm (CA group: 7%, control group:
0.4%; p = 0.0003) which were more frequent in the CA
group, the baseline characteristics were similarly distrib-
uted in both groups. Forty eight percent of the patients
had aneurysmal involvement of more than one coronary
vessel. The most frequent location of CA was the right cor-
onary artery. In most cases, this involvement was classi-
fied as diffuse. The maximal diameter of the aneurysmal
segments was 6.6 ± 1.2 mm.
Regarding ACE I/D genotypes, there was no statistically
significant difference in the baseline characteristics both
in the CA group and in the control group (Table 1). The
distributions of the three genotypes were similar in both
groups: CA: 13%, 46%, and 41% for II, ID, and DD
respectively; controls: 18%, 41%, and 41% for II, ID, and
DD respectively; p = 0.45. The proportions of D allele
were 64% in the CA group and 62% in the control group;
p = 0.58.
Regarding AT1 receptor A/C genotypes, there was no sta-
tistically significant difference in the baseline characteris-
tics both in the CA group and in the control group (Table
2). The distributions of the three genotypes were similar
in both groups: CA: 54%, 41%, and 5% for AA, AC, and
CC respectively; controls: 55%, 33%, and 12%, for AA,
AC, and CC respectively; p = 0.08. The proportions of C
allele were 26% in the CA group and 29% in the control
group; p = 0.36.
Table 1: Clinical and angiographic characteristics in CA and control patients as a function of the ACE I/D polymorphism.
CA (n = 113) Controls (n = 226)
II (n = 15) ID (n = 52) DD (n = 46) II (n = 41) ID (n = 92) DD (n = 93)
Age, years 63 ± 13 64 ± 10 60 ± 13 64 ± 11 61 ± 11 62 ± 11
Body Mass Index, kg/m2 28.4 ± 5 27.3 ± 4 27.6 ± 4 27.3 ± 4 27.8 ± 12 26.6 ± 4
Male gender, % 93 92 87 73 83 81
Smoking, % 80 77 80 63 76 67
Hypercholesterolemia, % 87 79 80 88 71 75
Hypertension, % 40 40 48 46 53 47
Diabetes, % 13 13 20 24 27 23
Previous myocardial infarction, % 73 67 67 56 59 44
History of aortic aneurysm, % 7 4 11 2 0 0
Number of stenotic lesions, %
- Non significant 0 6 7 15 9 7
- Single-vessel 13 30 28 24 35 37
- Two-vessel 60 42 43 37 32 31
- Three-vessel 27 22 22 24 25 25
Coronary aneurysm(s) location, %
- Left Main 0 4 13 NA NA NA
- Left Anterior Descending Artery 60 52 50 NA NA NA
- Circumflex 67 34 35 NA NA NA
- Right Coronary Artery 67 74 72 NA NA NA
Number of vessel(s) with CA, %
- 1 33 56 52 NA NA NA
- 2 40 28 35 NA NA NA
- 3 27 16 13 NA NA NA
Type of aneurysm(s), %
- Diffuse 93 79 78 NA NA NA
- Focal 7 21 22 NA NA NAPage 4 of 7
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CA is a relatively rare manifestation of CAD. In the present
study, 2.9% of patients undergoing coronary angiography
had CA; previous studies have reported rates ranging
between 1 and 5% [20–23]. The exact mechanisms by
which CA may occur in response to atherosclerosis are
unknown but histological and clinical studies suggest that
processes similar to those implicated in abdominal aortic
aneurysms (AAA) may be involved [22]. Experimental
studies have linked angiotensin II to aneurysm formation.
Nishijo et al observed that angiotensin II stimulated aneu-
rysm formation in hypertensive transgenic mice that over-
produce angiotensin II [28]. Recently, Daugherty et al
found that continuous perfusion of angiotensin II was
associated with the formation of large AAA in atheroscle-
rotic apoE-/- mice with a dose-response effect [15]. More-
over, angiotensin II-induced AAA development was
significantly reduced by doxycycline, a broad spectrum
MMP inhibitor [19]. Furthermore, Huang et al showed
that ACE inhibition reduced the rate of spontaneous rup-
ture of the internal elastic lamina of the abdominal aorta
[29] and Liao et al reported total inhibition of elastase-
induced AAA in a rat model by treatment with 3 different
ACE inhibitors [30].
In humans, limited data are available regarding the impli-
cation of the RAS in aneurysm formation; however,
genetic association studies may provide interesting infor-
mation. Discordant results have been reported regarding
the ACE I/D polymorphism and abdominal aortic aneu-
rysm. Although Hamano et al failed to show any positive
correlation between this polymorphism and the occur-
rence of AAA [31], a recent study by Pola et al suggested
that the ACE DD genotype may be a risk factor for AAA in
normotensive patients [32]. In the present study, the dis-
tribution of the ACE I/D genotypes were similar in the CA
and the control groups, suggesting that the ACE I/D poly-
morphism is not an important determinant of CA forma-
tion. To the best of our knowledge, the association of the
AT1-R genotype with AAA has never been specifically ana-
lyzed. In the present study, the distribution of the AT1-R
genotypes were similar in the CA and the control groups,
suggesting that the AT1-R polymorphism is not an impor-
tant determinant of CA formation.
Study Limitations
The interpretation of negative results may be limited by a
relatively small sample size. With a statistical power of
80% and a significant value of 0.05, the sample size of this
Table 2: Clinical and angiographic characteristics in CA and control patients as a function of the AT1 receptor A/C polymorphism.
CA (n = 113) Controls (n = 226)
AA (n = 61) AC (n = 46) CC (n = 6) AA (n = 123) AC (n = 75) CC (n = 28)
Age, years 61 ± 13 64 ± 11 63 ± 7 61 ± 11 61 ± 12 64 ± 9
Body Mass Index, kg/m2 27.2 ± 4 28.4 ± 4 26 ± 6 27.7 ± 10 26.4 ± 5 27.3 ± 5
Male gender, % 90 91 83 80 81 75
Smoking, % 80 78 67 67 75 71
Hypercholesterolemia, % 80 83 67 75 73 86
Hypertension, % 41 43 67 54 41 54
Diabetes, % 16 13 33 26 19 36
Previous myocardial infarction, % 70 72 17 54 53 39
History of aortic aneurysm, % 10 4 0 0 0 4
Number of stenotic lesions, %
- Non significant 6 4 0 6 11 22
- Single-vessel 22 29 67 32 37 32
- Two-vessel 45 51 0 33 31 32
- Three-vessel 27 16 33 29 21 14
Coronary aneurysm(s) location, %
- Left Main 7 7 17 NA NA NA
- Left Anterior Descending Artery 47 60 50 NA NA NA
- Circumflex 33 49 17 NA NA NA
- Right Coronary Artery 72 73 67 NA NA NA
Number of vessel(s) with CA, %
- 1 60 40 0 NA NA NA
- 2 27 38 50 NA NA NA
- 3 13 22 50 NA NA NA
Type of aneurysm(s), %
- Diffuse 80 80 83 NA NA NA
- Focal 20 20 17 NA NA NAPage 5 of 7
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quency of the ACE D allele and a 10% difference in the fre-
quency of the AT1-R C allele. However, the 113 patients
with CA were prospectively recruited by a systematic anal-
ysis of 3862 consecutive angiography procedures; the
design of larger studies would imply a multicentric
recruitment. Finally, this was an angiographic study; as
shown by Maehara et al, the use of intravascular ultra-
sound may allow a better analysis of aneurysmal segments
[33].
Conclusions
Epidemiological studies have suggested a link between
RAS polymorphisms and CAD [4–8]. Our results provide
further information on the role of RAS polymorphisms on
specific mechanisms implicated in CAD. We [14] and oth-
ers [34] previously reported that the ACE I/D polymor-
phism was associated with neointimal hyperplasia in
response to coronary stent implantation. We also showed
that the AT1-R polymorphism (but not the ACE I/D poly-
morphism) was associated with coronary artery vasocon-
striction in response to methylergonovine [12]. By
contrast, the ACE I/D and AT1-R polymorphisms are not
associated with restenosis of coronary arteries after bal-
loon angioplasty [13], a process which is mainly related to
constrictive vessel remodeling [35]; in the present study,
we focused on another form of vessel remodeling, aneu-
rysm formation, which again was not associated with
either the ACE I/D or the AT1-R polymorphisms.
Although an activated RAS may theoretically promote
aneurysm formation via mechanisms such as an induc-
tion of metalloproteinases [18] or an increased inflamma-
tion [15], the 2 RAS polymorphisms analyzed in this
study are not associated with this process in coronary
arteries.
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